Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next-generation delivery systems
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR
Funding stage: Private
Location: San Francisco, CA, USA
Gene editing partnerships: Sarepta Therapeutics
GenEdit develops next-generation in vivo gene delivery systems. The company raised $26M in a Series A funding round in September 2021. The technology is based on non-lipid polymer nanoparticles, and the company yet has to disclose its leading pre-clinical programmes.